Barth Syndrome
"Barth Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Rare congenital X-linked disorder of lipid metabolism. Barth syndrome is transmitted in an X-linked recessive pattern. The syndrome is characterized by muscular weakness, growth retardation, DILATED CARDIOMYOPATHY, variable NEUTROPENIA, 3-methylglutaconic aciduria (type II) and decreases in mitochondrial CARDIOLIPIN level. Other biochemical and morphological mitochondrial abnormalities also exist.
Descriptor ID |
D056889
|
MeSH Number(s) |
C14.240.400.172 C14.280.400.172 C16.131.077.121 C16.131.240.400.172 C16.320.322.068 C16.320.565.398.224 C18.452.648.398.224
|
Concept/Terms |
Barth Syndrome- Barth Syndrome
- Syndrome, Barth
- 3-Methylglutaconicaciduria Type 2
- 3 Methylglutaconicaciduria Type 2
- 3-Methylglutaconicaciduria Type 2s
- Type 2, 3-Methylglutaconicaciduria
- 3-Methylglutaconicaciduria Type II
- 3-Methylglutaconicaciduria Type IIs
- MGA Type 2
- MGA Type 2s
- Type 2, MGA
- Type 2s, MGA
- MGA Type II
- MGA Type IIs
- Type II, MGA
- Type IIs, MGA
- 3-Methylglutaconic Aciduria, Type II
- 3 Methylglutaconic Aciduria, Type II
- Cardioskeletal Myopathy with Neutropenia and Abnormal Mitochondria
|
Below are MeSH descriptors whose meaning is more general than "Barth Syndrome".
- Diseases [C]
- Cardiovascular Diseases [C14]
- Cardiovascular Abnormalities [C14.240]
- Heart Defects, Congenital [C14.240.400]
- Barth Syndrome [C14.240.400.172]
- Heart Diseases [C14.280]
- Heart Defects, Congenital [C14.280.400]
- Barth Syndrome [C14.280.400.172]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Congenital Abnormalities [C16.131]
- Abnormalities, Multiple [C16.131.077]
- Barth Syndrome [C16.131.077.121]
- Cardiovascular Abnormalities [C16.131.240]
- Heart Defects, Congenital [C16.131.240.400]
- Barth Syndrome [C16.131.240.400.172]
- Genetic Diseases, Inborn [C16.320]
- Genetic Diseases, X-Linked [C16.320.322]
- Barth Syndrome [C16.320.322.068]
- Metabolism, Inborn Errors [C16.320.565]
- Lipid Metabolism, Inborn Errors [C16.320.565.398]
- Barth Syndrome [C16.320.565.398.224]
- Nutritional and Metabolic Diseases [C18]
- Metabolic Diseases [C18.452]
- Metabolism, Inborn Errors [C18.452.648]
- Lipid Metabolism, Inborn Errors [C18.452.648.398]
- Barth Syndrome [C18.452.648.398.224]
Below are MeSH descriptors whose meaning is more specific than "Barth Syndrome".
This graph shows the total number of publications written about "Barth Syndrome" by people in this website by year, and whether "Barth Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 0 | 1 | 1 | 2020 | 1 | 0 | 1 | 2021 | 1 | 0 | 1 | 2022 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Barth Syndrome" by people in Profiles.
-
Schweitzer GG, Ditzenberger GL, Hughey CC, Finck BN, Martino MR, Pacak CA, Byrne BJ, Cade WT. Elevated liver glycogenolysis mediates higher blood glucose during acute exercise in Barth syndrome. PLoS One. 2023; 18(8):e0290832.
-
Zegallai HM, Abu-El-Rub E, Mejia EM, Sparagna GC, Cole LK, Marshall AJ, Hatch GM. Tafazzin deficiency attenuates anti-cluster of differentiation 40 and interleukin-4 activation of mouse B lymphocytes. Cell Tissue Res. 2022 Dec; 390(3):429-439.
-
Zegallai HM, Abu-El-Rub E, Olayinka-Adefemi F, Cole LK, Sparagna GC, Marshall AJ, Hatch GM. Tafazzin deficiency in mouse mesenchymal stem cells promote reprogramming of activated B lymphocytes toward immunosuppressive phenotypes. FASEB J. 2022 08; 36(8):e22443.
-
Chatfield KC, Sparagna GC, Specht KS, Whitcomb LA, Omar AK, Miyamoto SD, Wolfe LM, Chicco AJ. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy. J Inherit Metab Dis. 2022 01; 45(1):111-124.
-
Le CH, Benage LG, Specht KS, Li Puma LC, Mulligan CM, Heuberger AL, Prenni JE, Claypool SM, Chatfield KC, Sparagna GC, Chicco AJ. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria. J Biol Chem. 2020 08 28; 295(35):12485-12497.
-
Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL, Judge DP, Lal AK, Markham LW, Parks WJ, Tsuda T, Wang PJ, Yoo SJ. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation. 2017 Sep 26; 136(13):e200-e231.
-
Wajner M, Goodman SI. Disruption of mitochondrial homeostasis in organic acidurias: insights from human and animal studies. J Bioenerg Biomembr. 2011 Feb; 43(1):31-8.
|
People ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|